OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
Zacks News
Here's Why You Should Hold on to OPKO Health (OPK) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.
OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and a few strategic agreements.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 6.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical, Inc. (ISRG) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 5.61% and 3.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.
OPKO Health (OPK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $3.51, moving +0.86% from the previous trading session.
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -1.25% move from the prior day.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -266.67% and 19.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, OPKO Health (OPK) closed at $3.15, marking a +0.32% move from the previous day.
Pfizer (PFE) Gets EU Nod for Somatrogon & Pneumococcal Jab
by Zacks Equity Research
Pfizer (PFE) gets approval for pediatric growth hormone deficiency drug, Ngenla (somatrogon) and 20-valent pneumococcal conjugate vaccine, Apexxnar, in Europe.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.
Analysts Estimate OPKO Health (OPK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quotient (QTNT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quotient (QTNT) delivered earnings and revenue surprises of -76% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $3.04 in the latest trading session, marking a -0.65% move from the prior day.
Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis
by Zacks Equity Research
Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.
OPKO Health (OPK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed at $2.87 in the latest trading session, marking a -1.37% move from the prior day.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Pfizer's (PFE), OPKO's BLA for Somatrogon Gets CRL From FDA
by Zacks Equity Research
The FDA issues a Complete Response Letter to Pfizer (PFE) and OPKO Health's biologics license application for somatrogon to treat growth hormone deficiency in pediatric patients.